x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0231362
| Product Information | |
|---|---|
| CAS No. | 5142-23-4 |
| Synonyms | NSC 66389 |
| Formula | C6H7N5 |
| Molecular Weight | 149.15 |
| SMILES | C[N]1C=NC(=C2N=CN=C12)N |
| Target | Vps34 and PI3Kγ |
| Product Description | 3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. |
| Format & Storage | |
|---|---|
| Purity | > 98% |
| Shipping | Shipped on dry ice. |
| Storage | Powder: -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months; -20 °C, 1 month |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
